ADT, intended for locally advanced cases of PrCa, is predicated on the fact that androgens (such as testosterone) can bind to and activate the androgen receptor (AR) into a transcription factor that promotes the expression of genes involved in neoplastic transformation and proliferation of prostate cells. This evidence concerns the gene AR and pure red-cell aplasia.